DelveInsight’s, "Recurrent or Metastatic Head and Neck cancer Pipeline Insight” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the Recurrent or Metastatic Head and Neck Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Recurrent or Metastatic Head and Neck Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Recurrent or Metastatic Head and Neck Cancer Pipeline Report to explore emerging therapies, key Recurrent or Metastatic Head and Neck Cancer Companies, and future Recurrent or Metastatic Head and Neck Cancer treatment landscapes @ Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook Report
Key Takeaways from the Recurrent or Metastatic Head and Neck Cancer Pipeline Report
- In February 2025:- Coordination Pharmaceuticals, Inc.:- This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer. Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck Cancer
- In February 2025:- Janssen Research & Development LLC:- The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, and amivantamab in addition to paclitaxel in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel.
- In February 2025:- Boehringer Ingelheim:- This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
- In February 2025:- Adlai Nortye Biopharma Co. Ltd:- This study is to assess the impact on overall survival of the combination of Buparlisib and paclitaxel compared to paclitaxel alone in patients with prior anti PD 1/anti PD L1 monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to or post, platinum-based therapy.
- DelveInsight’s Recurrent or Metastatic Head and Neck Cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck Cancer treatment.
- The leading Recurrent or Metastatic Head and Neck Cancer Companies such as Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
- Promising Recurrent or Metastatic Head and Neck Cancer Therapies such as docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.
Discover how the Recurrent or Metastatic Head and Neck Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Recurrent or Metastatic Head and Neck Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Recurrent or Metastatic Head and Neck Cancer Clinical Trials and Studies
Recurrent or Metastatic Head and Neck Cancer Emerging Drugs Profile
- Xevinapant: Merck
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive € 188 million upfront and up to € 710 million in regulatory and commercial milestones, as well as royalty payments
- SI B001: Sichuan Baili Pharmaceutical
SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and the activation of its downstreamsignal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, anddown-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.
The Recurrent or Metastatic Head and Neck Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Recurrent or Metastatic Head and Neck Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Recurrent or Metastatic Head and Neck Cancer Treatment.
- Recurrent or Metastatic Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Recurrent or Metastatic Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Recurrent or Metastatic Head and Neck Cancer market.
Get a detailed analysis of the latest innovations in the Recurrent or Metastatic Head and Neck Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Recurrent or Metastatic Head and Neck Cancer Unmet Needs
Recurrent or Metastatic Head and Neck Cancer Companies
Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
Recurrent or Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Recurrent or Metastatic Head and Neck Cancer Therapies and key Recurrent or Metastatic Head and Neck Cancer Developments @ Recurrent or Metastatic Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report
- Coverage- Global
- Recurrent or Metastatic Head and Neck Cancer Companies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie and others.
- Recurrent or Metastatic Head and Neck Cancer Therapies- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.
- Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Recurrent or Metastatic Head and Neck Cancer drug development? Find out in DelveInsight’s exclusive Recurrent or Metastatic Head and Neck Cancer Pipeline Report—access it now! @ Recurrent or Metastatic Head and Neck Cancer Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Recurrent or Metastatic Head and Neck cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Recurrent or Metastatic Head and Neck cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Lenvatinib: Eisai Co
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- SI B001: Sichuan Baili Pharmaceutical
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Revdofilimab: AbbVie
- Drug profiles in the detailed report…..
- Early Stage Products (Preclinical)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Recurrent or Metastatic Head and Neck cancer Key Companies
- Recurrent or Metastatic Head and Neck cancer Key Products
- Recurrent or Metastatic Head and Neck cancer- Unmet Needs
- Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
- Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
- Recurrent or Metastatic Head and Neck cancer Analyst Views
- Recurrent or Metastatic Head and Neck cancer Key Companies
- 27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
